Trasicor in angina pectoris: a double-blind trial.

Eighteen patients entered a double-blind trial of the beta-adrenergic blocking drug Trasicor in the treatment of angina pectoris. Six patients had to be withdrawn from the trial when substitution of placebo for Trasicor caused severe exacerbation of angina attacks. In these cases the frequency and severity of angina attacks fell to a minimum when Trasicor was re-established. A further 10 patients were significantly improved by Trasicor. Two patients showed no significant improvement. No side-effects were observed in doses ranging up to 400 mg. daily.